In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates.
about
Voriconazole in the management of nosocomial invasive fungal infections.Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations.Developments in the treatment of candidiasis: more choices and new challenges.Molecular mechanisms of drug resistance in clinical Candida species isolated from Tunisian hospitalsSubcutaneous cryptococcosis due to Cryptococcus diffluens in a patient with sporotrichoid lesions case report, features of the case isolate and in vitro antifungal susceptibilitiesNew generation azole antifungals in clinical investigation.New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations.Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study.Voriconazole: a broad spectrum triazole for the treatment of serious and invasive fungal infections.In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi.Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint.Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study
P2860
Q35166823-94011D53-BE44-4B65-9904-5FB4CDFA90C7Q36491819-CFA6FF0F-D260-4542-BEC8-94D0A2B89766Q36623050-86AEC1EE-E0EC-43CC-8156-01D9B056B0BDQ36969703-F0FAC2D6-90CA-4F99-8959-E96344451366Q37271714-D71B0932-5F24-43AA-9935-2CF5C4F7434CQ37579222-40F78DAF-DFE5-404F-9FCB-3964D3DC24A5Q37608276-0F3DBAD9-0934-451F-B3CB-7A86697C9761Q37918556-26BB3179-5C0B-4CFF-B342-AC0913AF2F0BQ39665961-63C9531D-9839-4EA1-B147-7DA8373D4D1FQ40189236-798D9B09-DC15-4621-A3EB-27DEBC13687CQ40668115-CE3413D8-3DB1-4636-A0E5-3A3E8BD76014Q42545839-4FC27D47-7181-424D-A40B-2995671DB160Q58697730-9D833322-65ED-4A53-BD3A-25A9F4515CEC
P2860
In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
In vitro activities of ravucon ...... tible clinical yeast isolates.
@ast
In vitro activities of ravucon ...... tible clinical yeast isolates.
@en
type
label
In vitro activities of ravucon ...... tible clinical yeast isolates.
@ast
In vitro activities of ravucon ...... tible clinical yeast isolates.
@en
prefLabel
In vitro activities of ravucon ...... tible clinical yeast isolates.
@ast
In vitro activities of ravucon ...... tible clinical yeast isolates.
@en
P2093
P2860
P1476
In vitro activities of ravucon ...... tible clinical yeast isolates.
@en
P2093
Alicia Gomez-Lopez
Emilia Mellado
Guillermo Garcia-Effron
Juan L Rodriguez-Tudela
Manuel Cuenca-Estrella
P2860
P304
P356
10.1128/AAC.48.8.3107-3111.2004
P407
P577
2004-08-01T00:00:00Z